Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charalabos-Markos Dintsios

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
International Journal of Technology Assessment in Health Care|October 7, 2010
Information on ethical issues in health technology assessment: how and where to find themSigrid Droste, Charalabos-Markos Dintsios, Andreas Gerber
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare DiseasesMichael Schlander, Charalabos-Markos Dintsios, Afschin Gandjour
Pharmacoeconomics|January 17, 2025
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target PopulationsGeorgia Pick, Dirk Müller, Charalabos-Markos Dintsios
GMS Health Technology Assessment|February 4, 2011
Coated stents to prevent restenosis in coronary heart diseaseVitali Gorenoi, Charalabos-Markos Dintsios, Anja Hagen
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 17, 2009
[Patient participation in defining and assigning importance to treatment outcomes--status quo and potential developments]Fülöp Scheibler, Inger M Scheike, Charalabos-Markos Dintsios
Systematic Reviews|December 1, 2018
Quantified patient preferences for lifestyle intervention programs for diabetes prevention-a protocol for a systematic reviewCharalabos-Markos Dintsios, Nadja Chernyak, Benjamin Grehl, et al.
The Patient|November 28, 2025
Women's Preferences in Early Pregnancy Loss Management: A Focus on Psychological Considerations Using the Analytic Hierarchy ProcessMirjam E C Peters, Andrea Icks, Charalabos-Markos Dintsios
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 27, 2020
Predictors of negotiated prices for new drugs in GermanyAfschin Gandjour, Sofia Schüßler, Thomas Hammerschmidt, et al.
GMS Health Technology Assessment|February 4, 2011
Intravascular brachytherapy for peripheral vascular diseaseVitali Gorenoi, Charalabos-Markos Dintsios, Matthias P Schönermark, et al.
Herz|May 16, 2009
[Health-economic modeling on the use of drug-eluting stents versus coronary artery bypass graft surgery in coronary heart disease]Vitali Gorenoi, Charalabos-Markos Dintsios, Matthias P Schönermark, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
International Journal of Technology Assessment in Health Care|October 7, 2010
Information on ethical issues in health technology assessment: how and where to find themSigrid Droste, Charalabos-Markos Dintsios, Andreas Gerber
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare DiseasesMichael Schlander, Charalabos-Markos Dintsios, Afschin Gandjour
Pharmacoeconomics|January 17, 2025
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target PopulationsGeorgia Pick, Dirk Müller, Charalabos-Markos Dintsios
GMS Health Technology Assessment|February 4, 2011
Coated stents to prevent restenosis in coronary heart diseaseVitali Gorenoi, Charalabos-Markos Dintsios, Anja Hagen
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 17, 2009
[Patient participation in defining and assigning importance to treatment outcomes--status quo and potential developments]Fülöp Scheibler, Inger M Scheike, Charalabos-Markos Dintsios
Systematic Reviews|December 1, 2018
Quantified patient preferences for lifestyle intervention programs for diabetes prevention-a protocol for a systematic reviewCharalabos-Markos Dintsios, Nadja Chernyak, Benjamin Grehl, et al.
The Patient|November 28, 2025
Women's Preferences in Early Pregnancy Loss Management: A Focus on Psychological Considerations Using the Analytic Hierarchy ProcessMirjam E C Peters, Andrea Icks, Charalabos-Markos Dintsios
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 27, 2020
Predictors of negotiated prices for new drugs in GermanyAfschin Gandjour, Sofia Schüßler, Thomas Hammerschmidt, et al.
GMS Health Technology Assessment|February 4, 2011
Intravascular brachytherapy for peripheral vascular diseaseVitali Gorenoi, Charalabos-Markos Dintsios, Matthias P Schönermark, et al.
Herz|May 16, 2009
[Health-economic modeling on the use of drug-eluting stents versus coronary artery bypass graft surgery in coronary heart disease]Vitali Gorenoi, Charalabos-Markos Dintsios, Matthias P Schönermark, et al.
Pageof 5